Nodal marjinal zon lenfomada rituksimab-bendamustin sonrası ağır tümör lizis sendromu
Öz
Anahtar Kelimeler
Kaynakça
- Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.
- Çetinkaya R., Yılmaz V. T. Tümör Lizis Sendromu. Turkiye Klinikleri J Nephrol-Special Topics. 2014;7(1):74-7.
- Otrock ZK, Hatoum HA, Salem ZM. Acute tumor lysis syndrome after rituximab administration in Burkitt’s lymphoma. Intern Emerg Med 2008;3:161–63.
- Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89 –91.
- Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247–50.
- Francescone SA, Murphy B, Fallon JT, et al. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder. Transplant Proc 2009;41:1946 – 48.
- Yang B, Lu XC, Yu RL, et al. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma. Am J Med Sci. 2012;343(4):337-41. doi:10.1097/MAJ.0b013e318244db6f
- Naithani R, Bhat A, Bhasin A. Bendamustine induced tumor lysis syndrome with acute renal failure in chronic lymphocytic leukemia. Indian J Cancer. 2014;51(3):380-1. doi:10.4103/0019-509X.146740
Ayrıntılar
Birincil Dil
Türkçe
Konular
Sağlık Kurumları Yönetimi
Bölüm
Olgu Sunumu
Yazarlar
Gökhan Çolak
*
Türkiye
İrfan Yavaşoğlu
Türkiye
Yayımlanma Tarihi
12 Aralık 2022
Gönderilme Tarihi
5 Şubat 2022
Kabul Tarihi
27 Haziran 2022
Yayımlandığı Sayı
Yıl 2022 Cilt: 61 Sayı: 4